CAR-T Cell Therapy Denied by Insurance? How to Appeal
Insurer denied CAR-T cell therapy (Yescarta, Kymriah, Breyanzi)? These FDA-approved cancer treatments cost $400K–$500K — and insurers routinely deny them as 'experimental.' Here's how to fight back.
CAR-T Cell Therapy Denied by Insurance? How to Appeal
CAR-T cell therapy represents one of the most significant advances in cancer treatment in decades. It has produced complete remissions in patients with blood cancers who had exhausted every other option. It is also FDA-approved. Yet insurers routinely deny CAR-T claims as "experimental" or "not medically necessary" — a classification that is legally and clinically wrong when the treatment is FDA-approved for the patient's specific indication.
If your CAR-T therapy was denied, you can fight back. And the odds are in your favor.
What CAR-T Cell Therapy Is
CAR-T (chimeric antigen receptor T-cell) therapy involves extracting a patient's own immune cells, genetically engineering them to recognize and attack cancer cells, and reinfusing them. It is a one-time treatment with the potential for durable remission.
FDA-approved CAR-T products include:
- Yescarta (axicabtagene ciloleucel): relapsed/refractory large B-cell lymphoma (DLBCL), follicular lymphoma
- Kymriah (tisagenlecleucel): pediatric and young adult ALL, relapsed/refractory large B-cell lymphoma
- Breyanzi (lisocabtagene maraleucel): relapsed/refractory large B-cell lymphoma, CLL, mantle cell lymphoma
- Carvykti (ciltacabtagene autoleucel): relapsed/refractory multiple myeloma
- Abecma (idecabtagene vicleucel): relapsed/refractory multiple myeloma
Cost ranges from $400,000 to $500,000 per infusion, which is why insurers scrutinize these claims intensely. That cost does not make the treatment experimental or unnecessary. It makes it expensive. Those are not the same thing.
Why CAR-T Claims Get Denied
"Experimental or investigational." This is the most common denial reason — and the most clearly wrong one. FDA approval establishes that a treatment is safe and effective. A treatment cannot simultaneously be FDA-approved and experimental for the indication it was approved for. These are mutually exclusive categories.
"Not medically necessary." Insurers may argue that other treatments remain available. For relapsed/refractory cases where CAR-T is indicated, NCCN guidelines designate CAR-T as standard of care, meaning the medical necessity standard is met by definition.
"No in-network provider." CAR-T therapy is administered at specialized academic medical centers. Many patients have no in-network CAR-T center within a reasonable distance. This does not make the treatment uncoverable — it triggers network adequacy protections.
The Core Legal Argument: FDA Approval Defeats "Experimental"
Under the ACA and most state insurance laws, insurers cannot deny FDA-approved treatments as experimental when the treatment is approved for the patient's specific indication. If the FDA has approved Yescarta for relapsed/refractory DLBCL, an insurer cannot call it experimental for a patient with relapsed/refractory DLBCL. Period.
This argument wins at External Independent Review: Complete Guide" class="auto-link">external review consistently. Independent reviewers understand that FDA approval is the legal and clinical standard for "not experimental," and they apply that standard.
ClaimBack generates a professional appeal letter in 3 minutes — citing real insurance regulations for your country. Get your free analysis →
NCCN Guidelines and Medical Necessity
The National Comprehensive Cancer Network (NCCN) is the authoritative source for oncology treatment standards. NCCN Category 1 recommendations represent the highest level of evidence — uniform NCCN consensus based on high-level evidence.
Every major FDA-approved CAR-T product has NCCN Category 1 or 2A designation for its approved indication. Print the relevant NCCN guideline page and include it in your appeal. When NCCN Category 1 evidence supports the treatment, a medical necessity denial has no clinical foundation.
Navigating Prior Authorization Denied: How to Appeal" class="auto-link">Prior Authorization
Prior authorization for CAR-T must be obtained before treatment begins. The PA package should include:
- A detailed letter from your treating oncologist documenting diagnosis, pathology, prior lines of therapy, and rationale for CAR-T
- NCCN guideline pages confirming CAR-T as standard of care for your specific indication and line of therapy
- FDA approval label for the specific product
- Documentation of prior chemotherapy regimens and outcomes
- Hospital/center credentials confirming the infusion site is an authorized treatment center
Time matters in oncology. If a PA is denied, file an urgent appeal immediately. Most states require insurers to respond to urgent appeals within 72 hours.
Network Adequacy: When There Is No In-Network CAR-T Center
If your insurer denies coverage because the treating center is out of network, invoke network adequacy rules. Insurers are required to maintain adequate provider networks. When no in-network provider exists for a covered service — and CAR-T is a covered service if it is FDA-approved for your indication — the insurer must either:
- Cover the out-of-network provider at in-network cost-sharing, or
- Execute a single case agreement with the treating center
Request a single case agreement in writing. Have your oncologist document why the specific center is medically required (e.g., it is an authorized CAR-T center of excellence with the specific manufacturing authorization for the product prescribed). Copy your state insurance commissioner on the request if the insurer is slow to respond.
External Review: The Strongest Tool Available
Request external review the moment your internal appeal is denied. IROs consistently overturn CAR-T denials when the patient presents FDA approval documentation plus NCCN guidelines. The logic is airtight: FDA approval means not experimental; NCCN Category 1 means medically necessary. There is no defensible basis for denial when both are established.
Documentation Checklist
- Denial letter with specific denial reason and clinical criteria cited
- FDA product label for the specific CAR-T therapy (available at FDA.gov)
- NCCN guideline pages for the specific cancer type and line of therapy
- Oncologist letter documenting diagnosis, prior therapy, and CAR-T rationale
- Pathology report confirming the specific indication (e.g., DLBCL, FL)
- Records of all prior chemotherapy regimens and response/failure
- Treating center's CAR-T program authorization documentation
- Network adequacy complaint (if out-of-network denial)
- Single case agreement request letter (if applicable)
Fight Back With ClaimBack
ClaimBack analyzes your CAR-T denial, identifies the winning arguments, and generates an oncologist-ready appeal package built around FDA approval and NCCN guidelines.
Start your free appeal analysis at ClaimBack
Free analysis · No credit card required · Takes 3 minutes
Related Reading
How much did your insurer deny?
Enter your denied claim amount to see what you could recover.
Your insurer is counting on you giving up.
Most people do. Less than 1% of denied claimants ever appeal — even though the majority who do win. ClaimBack was built by people who were denied, who fought back, and who refused to accept "no" from an insurer.
We give you the same appeal arguments that attorneys use — in 3 minutes, for free. Your denial deadline is ticking. Don't let it expire.
Free analysis · No credit card · Takes 3 minutes
Related ClaimBack Guides